08/03/2022
We are pleased to announce that the Company has applied for registration of its NanoshieldTM Film line as a Class I medical device with the UK-based Medicines and Healthcare products Regulatory Agency (MHRA) for the UKCA (UK Conformity Assessed) Mark. The NanoshieldTM product, which is a protective film employing a transparent resin with activated copper exhibiting antimicrobial and antiviral properties, will now be able to be marketed for a range of medical and non-medical applications in the United Kingdom.
Commenting on the submission Nanoveu’s Managing Director and CEO, Alfred Chong, said: “Nanoveu continues to support its Nanoshield product in a range of international markets and is exceptionally pleased that it has been filed for registration as a Class I medical device in the UK. This is important as it enhances the reach of our products, but also builds confidence amongst end users that Nanoshield is accepted in major markets such as the UK. The registration quickly follows similarly positive regulatory news with the product receiving EPA Approval in the USA.
“By any measure, the UK is one of the largest healthcare markets, with the UK’s National Health Service being one of the world’s largest employers, and the nation is also home to a number of other major health organisations. Given its global significance, the UK is an important target for Nanoveu.
“Nanoveu will continue to make regulatory submissions to key medical markets across the globe and will endeavour to keep shareholders updated as further progress is made.”
Read Announcement: https://buff.ly/3ITTwgv
$NVU
